| Related Information: |
| The United Kingdom: Ulipristal acetate 5mg (Esmya): further restrictions due to ... 上載於 2021-02-19 |
| European Union: Ulipristal acetate for uterine fibroids: EMA recommends restrict... 上載於 2020-11-14 |
| Singapore: Voluntary withdrawal of Esmya (ulipristal acetate) Tablet 5mg by Zuel... 上載於 2020-10-10 |
| Canada: FIBRISTAL (ulipristal acetate tablets, 5 mg): Voluntary withdrawal in Ca... 上載於 2020-10-05 |
| Canada: Recall: Fibristal 5mg Tablet (English only) 上載於 2020-09-29 |
| Singapore: Temporary suspension of sales of Esmya (ulipristal acetate) tablet 5 ... 上載於 2020-09-19 |
| Canada: Health Canada reviews safety of drug Fibristal (ulipristal acetate) agai... 上載於 2020-09-17 |
| European Union: PRAC recommends revoking marketing authorisation of ulipristal a... 上載於 2020-09-05 |
| 台灣：回收恩惜膜5毫克錠劑Esmya 5mg tablets 上載於 2020-04-14 |
| Singapore: Temporary suspension of the sales of Esmya (ulipristal acetate) Table... 上載於 2020-04-03 |
| Singapore: Temporary suspension of the sales of Esmya (ulipristal acetate) Table... 上載於 2020-03-27 |
| The United Kingdom: Class 2 Medicines Recall: Esmya 5mg tablets (English only) 上載於 2020-03-19 |
| The United Kingdom: Esmya (ulipristal acetate): suspension of the licence due to... 上載於 2020-03-19 |
| EMA recommended the suspension of ulipristal acetate for uterine fibroids during... 上載於 2020-03-16 |
| European Union: Suspension of ulipristal acetate for uterine fibroids during ong... 上載於 2020-03-14 |
| Singapore: Risk of serious liver injury with Esmya (ulipristal acetate) (English... 上載於 2019-09-13 |
| Singapore: Esmya (ulipristal acetate) and risk of serious liver injury (English ... 上載於 2019-04-04 |
| Canada: Health Canada safety review finds possible link between Fibristal and ri... 上載於 2019-01-12 |
| Canada: Summary Safety Review - Fibristal (5 mg ulipristal acetate) - Assessing ... 上載於 2018-09-11 |
| 英國：Esmya (醋酸烏利司他)和嚴重肝臟損害的風險：新的使用限制及在治療前、治療期間和治療後肝功能監測的要求 上載於 2018-08-25 |
| 新加坡：Esmya (醋酸烏利司他)肝臟損害風險的重要安全更新 上載於 2018-06-12 |
| 歐洲聯盟：Esmya：減少罕見但嚴重肝臟損傷風險的新措施 – 歐洲藥物監管局總結治療子宮纖維瘤藥物的審查 上載於 2018-06-02 |
| 歐洲聯盟：藥物警戒風險評估委員會建議減少治療纖維瘤藥物Esmya罕見但嚴重肝臟損傷風險的新措施 – 治療期間應定期接受肝臟測試 上載於 2018-05-19 |
| 歐洲聯盟：在歐洲藥物監管局進行審查時，服用Esmya (烏利司他)治療子宮纖維瘤的女性應定期接受肝臟測試。同時新患者不應開始接受治療。 上載於 2018-04-14 |
| 加拿大：衞生局審查Fibristal (醋酸烏利司他)新的潛在安全風險，一種用於治療纖維瘤的藥物 上載於 2018-03-16 |
| 英國：治療子宮纖維瘤的Esmya (醋酸烏利司他)：不應開始或重新開始治療;為現正使用和近來有使用藥物的病人監測肝功能 上載於 2018-03-09 |
| 新加坡：Esmya (醋酸烏利司他) Tablet 5mg潛在肝臟損害風險的重要安全更新 上載於 2018-02-21 |
| 英國：Esmya：不應開始新的療程直到另行通知 上載於 2018-02-20 |
| Women taking Esmya for uterine fibroids to have regular liver tests while EMA re... 上載於 2018-02-12 |
| 歐洲聯盟：在歐洲藥物監管局進行審查時，服用Esmya治療子宮纖維瘤的女性應定期接受肝臟測試。同時新患者不應開始接受治療。 上載於 2018-02-10 |
